Endpoint Milestone In AML: Kronos’ Entospletinib Trial Will Rely On Residual Disease
Executive Summary
Phase III study in newly diagnosed patients with NPM1-mutated AML could enable Kronos’ SYK-inhibitor to reach market two years earlier under accelerated approval than it would under a traditional endpoint, company says.